piroxicam (feldene) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis.   NCATS

Chemistry

  • SMILES: CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=CC=CC=C3S1(=O)=O
  • InChIKey: QYSPLQLAKJAUJT-UHFFFAOYSA-N
  • Mol. Mass: 331.346
  • ALogP: 1.58
  • ChEMBL Molecules:
    piroxicam betadex  
    piroxicam  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.0789 - $0.3963

United States

$0.0803 - $13.2173
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4-hydroxy-2-methyl-n-(2-pyridyl)-2h-1,2-benzothiazin-3-caboxyamid-1,1-dioxid | betamarc | brexicam | brexidol | brexin | cicladol | cp16171 | cp-16171 | feldene | feldene 20 | feldene p | flamatrol | kentene | larapam | piroflam 10 | piroflam 20 | piroxicam | piroxicam beta-cyclodextrin | piroxicam-beta-cyclodextrin | piroxicam-beta-cyclodextrin complex | piroxicam betadex | piroxicamum | pirozip 10 | pirozip 20 | pyroxycam

Organizations (60)

Research & Development (43)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (24)

Approved Indications (3)


 

Arthritis, Rheumatoid

Gout

Osteoarthritis

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Acute Pain (Phase 2/Phase 3)

Anesthesia (Phase 2/Phase 3)

Anorexia (Phase 2)

Cachexia (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Contraception, Postcoital (Phase 2/Phase 3)

Cytochrome P-450 CYP2C19 (Phase 4)

Dentin Sensitivity (Phase 3)

Dysmenorrhea (Phase 4)

General Surgery (Phase 4)

Hypertension (Phase 4)

Osteoarthritis, Knee (Phase 2)

Pain (Phase 4)

Pain, Postoperative (Phase 2/Phase 3)

Pulpitis (Phase 4)

Renal Colic (Phase 2)

Tennis Elbow (Phase 2/Phase 3)

Tooth Abnormalities (Phase 4)

Toothache (Phase 3)

Weight Loss (Phase 2)

Wound Infection (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial Organizations: 43

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue